(Q38227113)

31 August 2017

Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease (English)

1 reference

31 August 2017

1 reference

Mona Hassan

1

1 reference

31 August 2017

Waqas Qureshi

2

1 reference

31 August 2017

Laila S Sroujieh

3

1 reference

31 August 2017

Derar Albashaireh

4

1 reference

31 August 2017

Sara BouMalham

5

1 reference

31 August 2017

Meghan Liroff

6

1 reference

31 August 2017

Waseem Amjad

7

1 reference

31 August 2017

Fatima Khalid

8

1 reference

31 August 2017

Hiba Hadid

9

1 reference

31 August 2017

Zaid Alirhayim

10

1 reference

31 August 2017

language of work or name

1 reference

7 July 2014

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

31 August 2017

1 reference

31 August 2017

15

1 reference

31 August 2017

3

1 reference

31 August 2017

278-285

1 reference

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

31 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Parathyroid hormone and heart failure: novel biomarker strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Interrelationship between haemodynamic state and serum intact parathyroid hormone levels in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Relation of serum parathyroid hormone level to severity of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Serum intact parathyroid hormone levels predict hospitalisation for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

ICD patients with elevated defibrillation threshold: clinical behavior and therapeutic alternatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Hyperparathyroidism and the calcium paradox of aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Aldosterone antagonism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Aldosterone in chronic kidney and cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Interplay between sodium and calcium regulatory hormones: a clinically relevant research field

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Plasma parathyroid hormone and risk of congestive heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Poor outcome in end-stage heart failure patients with low circulating calcitriol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Aldosterone inhibition in patients with heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320314539180

21 January 2018

Identifiers

DOI

10.1177/1470320314539180

1 reference

31 August 2017

1 reference